Introducing NEUTROGENA CLINICAL(TM) with ION2COMPLEX(TM) Technology

LOS ANGELES, March 11 /PRNewswire/ -- After years of research and ten new technology patents, Neutrogena®, the #1 dermatologist-recommend skin care brand, introduces NEUTROGENA CLINICAL™, featuring a breakthrough new anti-aging technology known as ION2COMPLEX™ to revitalize the look of collagen-depleted skin.

(Photo: http://www.newscom.com/cgi-bin/prnh/20100311/NY68770-a )

(Photo: http://www.newscom.com/cgi-bin/prnh/20100311/NY68770-b )

To develop NEUTROGENA CLINICAL™, scientists at Neutrogena® looked to the power of bioelectricity, the body's innate electrical signaling system.  Bioelectricity directs physiological activities at the cellular level, meaning it allows cells to "talk" with one another and execute marching orders.  

After studying the field of bioelectricity for over two years Neutrogena® scientists discovered a way to create tiny essential ion-mineral conductors within a topical formulation.  Once activated they work  like "miniaturized batteries" to simulate bioelectricity and increase positive ion flow, to help minimize visible signs of collagen loss by increasing resilience of the skin for noticeably improved facial definition, and a reduction in the appearance of wrinkles and sagging skin.  

SKIN CARE TECHNOLOGY INSPIRED BY THE SCIENCE OF BIOELECTRICITY

Skin relies on bioelectricity to help maintain the creation of collagen.  As the body ages bioelectric signaling diminishes resulting in decreased cell-to-cell communication, which can lead to the reduction in production of essential proteins, such as collagen.

"Diminished bioelectrical signaling has been observed in older skin.  These changes may result in decreased cell-to-cell communication and consequently might affect the balance of healthy turnover in the skin, resulting in visible signs of aging like wrinkles and sagging skin," says dermatologist Jane Khoury, M.D. who appears in the NEUTROGENA CLINICAL™ advertisements.

By mimicking optimal levels of bioelectricity, the ION2COMPLEX™ technology in NEUTROGENA CLINICAL™ creates a gentle microcurrent that reawakens collagen-depleted skin.

A TWO-PART SKIN CARE SYSTEM DESIGNED TO ACTIVATE ON CONTACT TO PHYSICALLY STIMULATE SKIN

The NEUTROGENA CLINICAL™ skin care regimen begins with the application of the ION2COMPLEX™ Gel Serum, which contains essential ion-mineral conductors, a proprietary fusion of zinc and copper minerals.  The serum is immediately followed by the second step of an Activating Cream, either a SPF 30, Eye or Night formula, to "turn on" the conductors in the ION2COMPLEX™ Gel Serum.  Enhanced with Tetrol-E ™, the Activating Creams maximize the power of the ION2COMPLEX™ technology.

Unlike other products and technologies in the marketplace NEUTROGENA CLINICAL™ physically stimulates skin and, because it does not rely on chemical reactions, it is well tolerated by all skin types.

CLINICALLY PROVEN RESULTS

In self-assessed clinical trial, 100% of subjects using NEUTROGENA CLINICAL™ saw improvement in lines, wrinkles, firming or elasticity.  

NEUTROGENA CLINICAL™ is not only more affordable than the #1 department store product; it was proven to outperform it as well.  In a blind dermatologist-assessed 12 week study the NEUTROGENA CLINICAL™ Facial Lifting Wrinkle Treatment Night was proven 10X more effective than the #1 department store product at improving the look of wrinkles, crow's feet and sagging skin after just four weeks.  

Ninety-one percent of study subjects using the NEUTROGENA CLINICAL™ Lifting Wrinkle Treatment Starter System had visible improvements in skin firmness in just four weeks and 88% of subjects using the NEUTROGENA CLINICAL™ Eye Lift Contouring Treatment saw improvement in the appearance of puffiness and dark circles.

THE NEUTROGENA CLINICAL™ SKIN CARE LINE:

Each product in the NEUTROGENA CLINICAL™ line comes with the ION2COMPLEX™ Gel Serum and a specifically formulated Activating Cream with Tetrol-E™.  A clinically proven firming ingredient derived from amino acids, Tetrol-E™ lifts and redefines skin for a visibly firmer and more lifted look.  Further enhanced with silicones the Activating Creams smooth skin and, over time, refines it as well.

The Facial Lifting Wrinkle Treatment SPF 30 features an SPF 30 Activating Cream formulated with Helioplex® technology.  Exclusive to Neutrogena, Helioplex® technology is engineered to deliver long-last and highly photostable UVA/UVB protection.  

The Eye Activating Cream in the Eye Lift Contouring Treatment is formulated with brightening minerals for an instantly more luminous look and the Night Activating Cream in the Facial Lifting Wrinkle Treatment Night is formulated with rich moisturizers and silicones for extra hydration.

The three NEUTROGENA CLINICAL™ products are available individually for $39.99 or as a starter system for $49.99.  The Lifting Wrinkle Treatment Starter System is comprised of an ION2COMPLEX™ Gel Serum, an SPF 30 Activating Cream and an Eye Activating Cream.

NEUTROGENA CLINICAL™ arrives in stores the first week of March and is currently available at www.neutrogenaclinical.com.  Through April 30, 2010 a $15 rebate is available on any NEUTROGENA CLINICAL™ system.  

The NEUTROGENA CLINICAL™ skin care line includes:

NEUTROGENA CLINICAL™ Facial Lifting Wrinkle Treatment SPF 30 - $39.99

NEUTROGENA CLINICAL™ Eye Lift Contouring Treatment - $39.99

NEUTROGENA CLINICAL™ Lifting Wrinkle Treatment Starter System - SPF 30 and Eye - $49.99

NEUTROGENA CLINICAL™ Facial Lifting Wrinkle Treatment Night - $39.99

About Neutrogena®

A worldwide leader in premium, dermatologist-recommended skin, hair and cosmetics products, Neutrogena® Corporation has been providing consumers with health and beauty improvements for over 40 years.  The Company manufactures and markets a line of premium-priced skin and hair care products that are distributed in more than 70 countries.  Headquartered in Los Angeles, Neutrogena® is a subsidiary of Johnson & Johnson, the world's most comprehensive and broadly based health care products company.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Neutrogena®'s and/or Johnson & Johnson's expectations and projections.  Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment.  A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2010.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  Neither Neutrogena® nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.)

SOURCE Neutrogena